IMPORTANT NOTICE: We have recently been made aware of fraudulent WhatsApp groups and imitation websites appearing to look like Coller Capital and exploiting our brand. Take caution and read the full notice.

X

Transaction type: GP-led

Shawbrook

In July 2017 CIP VII invested £125m into the public to private acquisition of Shawbrook Bank by Pollen Street Capital and BC Partners.

J C Flowers

In July 2016, CIP VI and CIP VII committed $288m to a GP-led transaction: a liquidity offer made to J C Flowers investors.

Irving Place Capital

In July 2015, CIP VI was the lead investor in a transaction, committing $645m, which allowed Irving Place Capital to reposition its 2006-vintage fund and establish a new investment vehicle.

American Capital

In May 2014, CIP VI was a leading member of an investor group which established American Capital’s third private equity fund, that consisted of seven companies from previous funds and capital for new investments.

Crédit Agricole

In December 2011, CIP VI acquired 100% of Crédit Agricole Private Equity (CAPE) and the majority of the underlying funds that CAPE manages.

3i

In September 2009, CIP V, purchased the majority of 3i’s remaining venture portfolio of technology and life sciences companies alongside HarbourVest Partners and DFJ Esprit. Coller Capital won Venture Capital Deal of the Year, 2009 for this transaction.

SVG Capital plc

In February 2009, CIP V participated in an innovative rights issue and share placement by SVG Capital plc – the major investor in Permira buyout funds. Through this rights issue, CIP V acquired a 20% stake in the business.

Royal Dutch Shell

In March 2007, CIP V established a $1bn joint venture with Shell to develop a portfolio of 34 investments. The joint venture structure enables Shell to maintain its existing strategic links with the portfolio companies, whilst benefiting from Coller Capital’s expertise and resources as a financial investor.

ABN AMRO

In December 2006, CIP IV formed a €193m joint venture with ABN AMRO Capital. Forbion Capital Partners span out of the bank to manage the portfolio of 26 life science companies.

ICICI Venture

In January 2006, CIP IV invested in ICICI Venture’s India Advantage Fund I – India’s first secondaries transaction. Coller’s proposals were tailored to meet the needs of individual sellers.